The diagnostic value of T1 mapping and APTw imaging in chronic kidney disease

Share this content in WeChat

• Clinical Article •

WANG Yue JU Ye BU Xinmiao CHEN Lihua WANG Nan LIU Ailian

Cite this article as: WANG Y, JU Y, BU X M, et al. The diagnostic value of T1 mapping and APTw imaging in chronic kidney disease[J]. Chin J Magn Reson Imaging, 2023, 14(2): 56-60, 67. DOI:10.12015/issn.1674-8034.2023.02.010.

Abstract

[Abstract] Objective To explore the value of T1 mapping and amide proton transfer weighted (APTw) imaging in differentiating chronic kidney disease (CKD) patients from healthy people.Materials and Methods A total of 21 cases of patients (6 females, 15 males) with CKD who underwent 3.0 T MRI from August 2019 to October 2020 were retrospectively collected. All patients were diagnosed according to the clinical practice guidelines of CKD in the department of nephrology of the First Affiliated Hospital of Dalian Medical University. At the same time, the data of 24 healthy volunteers were collected as the control group. All raw images were imported into the ISP workstation to generate pseudo-color images. Regions of interest (ROIs) of 10-20 mm² were placed in the cortex and medulla, respectively. The ROIs were selected from the upper, middle and lower pole of the kidney by two radiologists in a double-blind method, avoiding the renal sinus, large blood vessels and perirenal tissues. The T1 values and APT values of the cortex and medulla were statistically analyzed by SPSS 26.0 software. Intra-class correlation coefficients (ICC) were used to test the consistency of the measurement results between observers. Independent sample t test or Mann-Whitney U test was used to analyze the difference of parameter values between the two groups according to the normal distribution of data, and P＜0.05 was considered statistically significant. Receiver operating characteristic (ROC) curve was used to analyze the diagnostic efficacy of each parameter. The corresponding threshold, sensitivity and specificity were obtained according to the maximum Youden index, and the area under the curve (AUC) was calculated.Results The inter-observer agreement was good (ICC＞0.75). The renal cortical T1 value and cortical APT value in CKD group were significantly higher than those in healthy control group (P＜0.05). The AUC value of T1 value of left renal cortex in differentiating CKD was 0.887, the sensitivity was 66.7%, and the specificity was 100.0%. The AUC value of APT value of left renal cortex in identifying CKD was 0.966, with a sensitivity of 95.2% and a specificity of 95.8%. The AUC value of T1 value of right renal cortex in differentiating CKD was 0.960, the sensitivity was 76.2%, and the specificity was 100.0%. The APT value of right renal cortex had a AUC value of 0.921, a sensitivity of 85.7%, and a specificity of 91.7% for identifying CKD.Conclusions T1 mapping and APTw imaging can noninvasiously and effectively identify CKD. The quantitative parameters based on T1 mapping and APTw imaging can reflect the structural and functional changes of the left and right kidneys to a certain extent, which is expected to provide certain reference value for clinical disease diagnosis.

[Keywords] chronic kidney disease；T1 mapping；amide proton transfer imaging；functional magnetic resonance imaging；differential diagnosis

Contributor Information

WANG Yue¹ JU Ye¹ BU Xinmiao¹ CHEN Lihua¹ WANG Nan¹ LIU Ailian^{1,
2*}

¹ Department of Radiology, the First Affiliated Hospital of Dalian Medical University, Dalian 116011, China

² Dalian Medical Imaging Artificial Intelligence Engineering Technology Research Center, Dalian 116011, China

*Correspondence to: Liu AL, E-mail: cjr.liuailian@vip.163.com

Conflicts of interest None.

Publication Information

Received 2022-08-02

Accepted 2023-01-12

DOI: 10.12015/issn.1674-8034.2023.02.010

Text

References

[1]

SHLIPAK M G, TUMMALAPALLI S L, BOULWARE L E, et al. The case for early identification and intervention of chronic kidney disease: conclusions from a Kidney Disease: improving Global Outcomes (KDIGO) Controversies Conference[J]. Kidney Int, 2021, 99(1): 34-47. DOI: 10.1016/j.kint.2020.10.012.

[2]

IKIZLER T A, CUPPARI L. The 2020 updated KDOQI clinical practice guidelines for nutrition in chronic kidney disease[J]. Blood Purif, 2021, 50(4/5): 667-671. DOI: 10.1159/000513698.

[3]

KIDNEY DISEASE: IMPROVING GLOBAL OUTCOMES KDIGO) DIABETES WORK GROUP. KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease[J]. Kidney Int, 2022, 102(5S): S1-S127. DOI: 10.1016/j.kint.2022.06.008.

[4]

GAO X, MEI C L. Interpretation of guideline for early screening, diagnosis, prevention and treatment of chronic kidney disease(2022 edition)[J]. Chin J Pract Intern Med, 2022, 42(9): 735-739. DOI: 10.19538/j.nk2022090108.

[5]

ALNAZER I, BOURDON P, URRUTY T, et al. Recent advances in medical image processing for the evaluation of chronic kidney disease[J/OL]. Med Image Anal, 2021, 69: 101960 [2022-08-01]. https://www.sciencedirect.com/science/article/abs/pii/S1361841521000062. DOI: 10.1016/j.media.2021.101960.

[6]

FARRAG N A, LOCHBIHLER A, WHITE J A, et al. Evaluation of fully automated myocardial segmentation techniques in native and contrast-enhanced T1-mapping cardiovascular magnetic resonance images using fully convolutional neural networks[J]. Med Phys, 2021, 48(1): 215-226. DOI: 10.1002/mp.14574.

[7]

ALABED S, SAUNDERS L, GARG P, et al. Myocardial T1-mapping and extracellular volume in pulmonary arterial hypertension: a systematic review and meta-analysis[J]. Magn Reson Imaging, 2021, 79: 66-75. DOI: 10.1016/j.mri.2021.03.011.

[8]

UGANDER M. Exercise CMR T1 mapping for myocardial ischemia testing: No gad, No drugs, No problem?[J]. JACC Cardiovasc Imaging, 2020, 13(3): 681-683. DOI: 10.1016/j.jcmg.2019.06.005.

[9]

WANG Q, LIU H F, ZHU Z H, et al. Feasibility of T1 mapping with histogram analysis for the diagnosis and staging of liver fibrosis: Preclinical results[J]. Magn Reson Imaging, 2021, 76: 79-86. DOI: 10.1016/j.mri.2020.11.006.

[10]

DEKKERS I A, PAIMAN E H M, DE VRIES A P J, et al. Reproducibility of native T1 mapping for renal tissue characterization at 3T[J]. J Magn Reson Imaging, 2019, 49(2): 588-596. DOI: 10.1002/jmri.26207.

[11]

WU J H, SHI Z Y, ZHANG Y, et al. Native T1 Mapping in Assessing Kidney Fibrosis for Patients With Chronic Glomerulonephritis[J/OL]. Front Med (Lausanne), 2021, 8: 772326 [2022-08-01]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8558353/. DOI: 10.3389/fmed.2021.772326.

[12]

GRAHAM-BROWN M P, SINGH A, WORMLEIGHTON J, et al. Association between native T1 mapping of the kidney and renal fibrosis in patients with IgA nephropathy[J/OL]. BMC Nephrol, 2019, 20(1): 256 [2022-08-01]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6621982/. DOI: 10.1186/s12882-019-1447-2.

[13]

FRIEDLI I, CROWE L A, BERCHTOLD L, et al. New magnetic resonance imaging index for renal fibrosis assessment: a comparison between diffusion-weighted imaging and T1 mapping with histological validation[J/OL]. Sci Rep, 2016, 6: 30088 [2022-08-01]. https://www.nature.com/articles/srep30088. DOI: 10.1038/srep30088.

[14]

ZHANG H, ZHOU J Y, PENG Y. Amide proton transfer-weighted MR imaging of pediatric central nervous system diseases[J]. Magn Reson Imaging Clin N Am, 2021, 29(4): 631-641. DOI: 10.1016/j.mric.2021.06.012.

[15]

MENG N, FANG T, FENG P Y, et al. Amide proton transfer-weighted imaging and multiple models diffusion-weighted imaging facilitates preoperative risk stratification of early-stage endometrial carcinoma[J]. J Magn Reson Imaging, 2021, 54(4): 1200-1211. DOI: 10.1002/jmri.27684.

[16]

LI J, LIN L J, GAO X M, et al. Amide Proton Transfer Weighted and Intravoxel Incoherent Motion Imaging in Evaluation of Prognostic Factors for Rectal Adenocarcinoma[J/OL]. Front Oncol, 2022, 11: 783544 [2022-08-01]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8761907/. DOI: 10.3389/fonc.2021.783544.

[17]

NISHIE A, TAKAYAMA Y, ASAYAMA Y, et al. Amide proton transfer imaging can predict tumor grade in rectal cancer[J]. Magn Reson Imaging, 2018, 51: 96-103. DOI: 10.1016/j.mri.2018.04.017.

[18]

JU Y, LIU A L, WANG Y, et al. Amide proton transfer magnetic resonance imaging to evaluate renal impairment in patients with chronic kidney disease[J]. Magn Reson Imaging, 2022, 87: 177-182. DOI: 10.1016/j.mri.2021.11.015.

[19]

WANG Y, LIU A L, JU Y, et al. Study on the correlation between APT and mDixon-Quant in the right renal cortex and medulla of patients with chronic kidney disease[J]. Chin J Magn Reson Imaging, 2022, 13(3): 71-75. DOI: 10.12015/issn.1674-8034.2022.03.014.

[20]

HECTORS S J, GARTEISER P, DOBLAS S, et al. MRI mapping of renal T1: basic concept[J]. Methods Mol Biol Clifton N J, 2021, 2216: 157-169. DOI: 10.1007/978-1-0716-0978-1_9.

[21]

GILLIS K A, MCCOMB C, PATEL R K, et al. Non-contrast renal magnetic resonance imaging to assess perfusion and corticomedullary differentiation in health and chronic kidney disease[J]. Nephron, 2016, 133(3): 183-192. DOI: 10.1159/000447601.

[22]

RUIZ-ORTEGA M, RAYEGO-MATEOS S, LAMAS S, et al. Targeting the progression of chronic kidney disease[J]. Nat Rev Nephrol, 2020, 16(5): 269-288. DOI: 10.1038/s41581-019-0248-y.

[23]

WOLF M, DE BOER A, SHARMA K, et al. Magnetic resonance imaging T1- and T2-mapping to assess renal structure and function: a systematic review and statement paper[J]. Nephrol Dial Transplant, 2018, 33(suppl_2): ii41-ii50. DOI: 10.1093/ndt/gfy198.

[24]

COX E F, BUCHANAN C E, BRADLEY C R, et al. Multiparametric renal magnetic resonance imaging: validation, interventions, and alterations in chronic kidney disease[J/OL]. Front Physiol, 2017, 8: 696 [2022-08-01]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5603702/.

[25]

MORA-GUTIÉRREZ J M, FERNÁNDEZ-SEARA M A, ECHEVERRIA-CHASCO R, et al. Perspectives on the Role of Magnetic Resonance Imaging (MRI) for Noninvasive Evaluation of Diabetic Kidney Disease[J/OL]. J Clin Med, 2021, 10(11): 2461 [2022-08-01]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8199575/. DOI: 10.3390/jcm10112461.

[26]

MA C J, LIU A L, TIAN S F, et al. Preliminary study on the application value of APTw combined with mDixon-quant sequence in differentiating early endometrial carcinoma from endometrial polyp[J]. J Clin Radiol, 2022, 41(2): 372-376. DOI: 10.13437/j.cnki.jcr.2022.02.007.

[27]

DONG W, LIU A L, CHEN A L, et al. Comparison of amide proton transfer-weighted and diffusion kurtosis imaging in quantifying rectal cancer with and without chemotherapy[J]. Chin J Med Imaging, 2022, 30(1): 54-59. DOI: 10.3969/j.issn.1005-5185.2022.01.012.

[28]

DONG W, CHEN A L, LIU A L, et al. Comparation of amide proton transfer-weighted and T2 mapping in quantifying rectal cancer with and without chemotherapy: a preliminary study[J]. Chin J Magn Reson Imaging, 2021, 12(7): 24-28. DOI: 10.12015/issn.1674-8034.2021.07.005.

[29]

LI X W, CHEN L H, WANG N, et al. Preliminary study on the application of amide proton transfer-weighted combined with mDixon-Quant imaging in differentiating bone metastasis of prostate cancer[J]. J China Clin Med Imaging, 2022, 33(8): 540-545. DOI: 10.12117/jccmi.2022.08.002.

[30]

MA C J, TIAN S F, SONG Q L, et al. Amide Proton Transfer-Weighted Imaging Combined With Intravoxel Incoherent Motion for Evaluating Microsatellite Instability in Endometrial Cancer[J/OL]. J Magn Reson Imaging, 2022, 57(2): 493-505 [2022-08-01]. https://onlinelibrary.wiley.com/doi/10.1002/jmri.28287. DOI: 10.1002/jmri.28287.

[31]

GASPAR A S, MALTÊS S, MARQUES H, et al. Myocardial T1 mapping with magnetic resonance imaging - a useful tool to understand the diseased heart[J]. Portuguese J Cardiol Off J Portuguese Soc Cardiol, 2022, 41(1): 61-69. DOI: 10.1016/j.repc.2021.04.005.

[32]

MARQUES T D S S, FERNANDES A M S, DANTAS JÚNIOR R N, et al. Clinical heart failure stratification through native T1 mapping: experience of a referral service[J]. Arq Bras Cardiol, 2021, 116(5): 919-925. DOI: 10.36660/abc.20190782.

[33]

JIA Z, WANG L H, JIA Y Q, et al. Detection of acute myocarditis using T1 and T2 mapping cardiovascular magnetic resonance: a systematic review and meta-analysis[J]. J Appl Clin Med Phys, 2021, 22(10): 239-248. DOI: 10.1002/acm2.13365.

[34]

SECCHI F, ALÌ M, MONTI C B, et al. Right and left ventricle native T1 mapping in systolic phase in patients with congenital heart disease[J]. Acta Radiol, 2021, 62(3): 334-340. DOI: 10.1177/0284185120924563.

[35]

SHANG F F, SHI Z Y, WANG Y, et al. Application of Native T1? mapping imaging in diabetic kidney disease[J]. Chin J Diabetes, 2022, 30(7): 507-512. DOI: 10.3969/j.issn.1006-6187.2022.07.006.

PREV A preliminary clinical application of T2 mapping-based radiomics on MRI in breast diseases

NEXT The value of ADC map and T2WI radiomics analysis of the primary tumor for prediction of bone metastases in prostate cancer

LINK

Tel & Fax: +8610-67113815 E-mail: editor@cjmri.cn